ACUT logo

AccuStem Sciences, Inc. Stock Price

OTCPK:ACUT Community·US$5.1m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

ACUT Share Price Performance

US$0.32
-0.18 (-36.00%)
US$0.32
-0.18 (-36.00%)
Price US$0.32

ACUT Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Medium-low risk with weak fundamentals.

7 Risks
0 Rewards

AccuStem Sciences, Inc. Key Details

US$0

Revenue

US$0

Cost of Revenue

US$0

Gross Profit

US$1.8m

Other Expenses

-US$1.8m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
-0.11
0%
0%
-0.7%
View Full Analysis

About ACUT

Founded
2013
Employees
4
CEO
Wendy Blosser
WebsiteView website
accustem.com

AccuStem Sciences, Inc., a clinical stage diagnostics company, focuses on developing and commercializing a suite of novel genomic tests for oncology care. It offers MSC test, a 24-micro RNA (miRNA) assay designed to help determine whether lung nodules identified by low dose computer tomography screening are benign or malignant. The company also provides StemPrintER, a 20-gene prognostic assay to predict the risk of distant recurrence in luminal breast cancer patients. The company has a partnership with EmeritusDX for the development of non-invasive blood testing technologies. AccuStem Sciences, Inc. was founded in 2013 and is headquartered in New York, New York.

Recent ACUT News & Updates

Recent updates

No updates